Live
- Awareness Program in agricultural College on the Dangers of Drug Abuse for Youth
- 3500-Year-Old Menhir in Kamsanpally Village: A Call for Preservation
- The Role of Artificial Intelligence in Radiology: Transforming Diagnosis and Patient Care
- Hindustan Zinc Ltd. Signs MoU with Rajasthan Government to Invest Rs 36 Crores in Education Development
- Sales and Marketing: Synchronising Steps for Success
- MATTER begins deliveries of AERA from Ahmedabad, inaugurates first of its kind Experience Hub
- Transforming Education Infrastructure is the key to National Development: Neeraj Sharma, Auxilo Finserve
- Crimson Becomes the First Indian School to Receive WELL Health-Safety Certification for Measures to Boost Physical and Mental Wellbeing
- Trackon Celebrates 20 Years of Innovation and Growth in Logistics
- Hero Motocorp showcases its future mobility vision at Eicma 2024
Phase-III clinical trial for Covaxin begins at NIMS in Hyderabad
Phase-III clinical trial for Covaxin begins at NIMS in Hyderabad
The Phase-III human clinical trails for Covaxin has begun at Nizam's Institute of Medical Sciences (NIMS) in Hyderabad on Monday.
The Phase-III human clinical trails for Covaxin has begun at Nizam's Institute of Medical Sciences (NIMS) in Hyderabad on Monday. A medical team at NIMS said that the vaccine will be given for 600 volunteers in the phase-III and will be monitored closely.
Phase-I and II trails have said to be successful as no volunteer developed any sign of illness. The Indian Council of Medical Research (ICMR) is planning to bring the vaccine by February. The vaccine is being jointly developed by Bharat Biotech and ICMR.
Bharat Biotech approached Drugs Controller General of India (DCGI) on October 2 for the phase-III trails of Covaxin and the permission was accorded at SEC meeting held in New Delhi on October 19.
The phase-III human trails of Covaxin are being carried out at 19 places including Delhi, Mumbai, Patna, Odisha and Lucknow.
